Smart dosing vs. scheduled shots: a fight to keep a serious autoimmune disease at bay

This study tested two different long-term treatment plans for patients with a serious autoimmune disease called ANCA-associated vasculitis, who were already in remission. The goal was to see which plan was better at preventing the disease from flaring up again. One plan gave rituximab infusions on a fixed schedule, while the other adjusted the timing based on regular blood test results. The trial involved 166 adults and followed them for over two years.